ESI was also found to inhibit the growth of human chronic myeloid leukemia cells by inhibiting NF-κB activation and NF-κB-regulated gene expression (Ichikawa et al., 2006). The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.